Skip to content
FrontierPicks

Filtered library · Theme

M&A & special situations theme · 78 dossiers

Dossiers in the M&A & special situations theme cluster — 78 names moving on shared catalysts.

DormantLast produced 23 August 2026, 28 days ago — outside the 14-day window the model counts as current work.

All 78 are dated research with a published kill line — the level named in advance that would prove the call wrong.

All dossiers
APGE Apogee Therapeutics, Inc. fresh SUPREME Apogee Therapeutics’ $135.11-per-share cash-acquisition thesis resolved with AbbVie’s completion on 2026-09-03. The 2026-09-14 Form 15 advances administrative closure, leaving no unresolved APGE acquisition catalyst. Earnings inflection · M&A & special situations · Precision biotech & therapeutics catalyst · ATAI AtaiBeckley Inc. fresh SUPREME AtaiBeckley's Lilly acquisition thesis resolved with completion on 2026-09-11, ending the pending-merger case. Remaining contingent payments depend on disclosed clinical and regulatory milestones; Nasdaq suspended ATAI effective 2026-09-14. Earnings inflection · M&A & special situations · Precision biotech & therapeutics analysed · DSGR Distribution Solutions Group, Inc. fresh SUPREME Distribution Solutions Group’s $35.00 cash acquisition remains a completion thesis, with the minority vote and closing settling the case. HSR clearance occurred on 2026-08-20; a daily close below $33.50 invalidates the price thesis. Earnings inflection · M&A & special situations analysed · ATKR Atkore Inc. fresh HIGH Atkore's $95.00 cash-merger thesis now turns on the October 7 shareholder vote and remaining approvals after September 14 US antitrust clearance. Completion before a weekly close below $88 constitutes success; termination negates the case. Earnings inflection · M&A & special situations · Industrial power & grid catalyst · CBZ CBIZ, Inc. fresh HIGH CBIZ’s signed $55.00 cash merger makes completion the central thesis; closing settles the case, while a daily close below $52 invalidates it. The expected 2026-09-10 antitrust milestone has elapsed, but its outcome and a shareholder-vote… Earnings inflection · M&A & special situations analysed · HZO MarineMax, Inc. HIGH MarineMax’s $53.00-per-share cash merger prices completion of the Safe Harbor transaction on the announced end-2026 timetable. Closing would settle the case; a weekly close below $50, termination or failure to complete by 2026-12-31 would… Earnings inflection · M&A & special situations catalyst · ITGR Integer Holdings Corporation HIGH Integer Holdings Corporation’s $127.00 cash acquisition by KKR remains a completion thesis, strengthened by the 2026-09-03 merger proxy. Completion by year-end 2026 would settle the case; a daily close below $118 invalidates it. Earnings inflection · M&A & special situations · Medtech & diagnostics catalyst · PSNL Personalis, Inc. fresh HIGH The MRD story has been overtaken by a live sale process: StreetInsider reported 2026-07-17 that Personalis retained Centerview, TD Securities and Cooley after takeover interest from Merck (already a >10% holder and 19% of Q1 revenue) plus… Earnings inflection · Medtech & diagnostics · Oncology & immunology catalyst · CMBT CMB.TECH NV fresh MEDIUM CMB.TECH's vessel-disposal and cash-return story supports further upside if the proposed October distribution is delivered. The case requires payment of $0.64 per share and a weekly close above $20.41 by 2026-10-31, before a weekly close… Special situation · Oil, energy & geopolitical · Freight & logistics catalyst · FA First Advantage Corporation MEDIUM Aug 6 flipped the frame: Q2 revenue $448.8M/+14.9% vs $415.0M consensus, adj EPS $0.35 vs $0.28, and the first FY guide raise of the cycle ($1.67–1.71B). Needham upgraded to Buy/$28, RBC to $24 — targets moved above spot for the first… Special situation · M&A & special situations catalyst · ALOT AstroNova, Inc. fresh SUPREME AstroNova’s $29.00 cash-merger thesis played out on 2026-08-26; its 2026-09-08 Form 15 resolves the remaining filing uncertainty. Only restoration of the former public equity would reopen the closed situation. Earnings inflection · M&A & special situations analysed · AVNS Avanos Medical, Inc. fresh SUPREME Avanos Medical’s $25.00-per-share cash-acquisition thesis was settled by completion on 2026-07-27. The company’s shareholder notice confirms that exchange trading has ended, leaving a completed transaction rather than an unresolved… Earnings inflection · M&A & special situations · Medtech & diagnostics analysed · CCRN Cross Country Healthcare, Inc. fresh SUPREME Cross Country Healthcare’s $13.25 cash-merger thesis resolved when Knox Lane completed the acquisition on 2026-07-21. Exchange-confirmed trading in the original common stock would contradict the completed-outcome assessment; the July 20… Earnings inflection · M&A & special situations · Managed care & health services analysed · CNTA Centessa Pharmaceuticals plc fresh SUPREME Centessa Pharmaceuticals’ acquisition closed on 2026-06-24; the remaining story is approval-linked contingent value. Qualifying regulatory approvals settle that question, while the final CNTA close on 2026-06-23 supplies no live price test. Earnings inflection · M&A & special situations · Precision biotech & therapeutics catalyst · CRNX Crinetics Pharmaceuticals, Inc. fresh SUPREME Crinetics Pharmaceuticals’ cash-merger thesis was resolved by Vertex’s 2026-09-01 acquisition at $85.00 per eligible share. Deregistration dates remain unverified; reinstated common-stock trading would overturn the terminal-equity… Earnings inflection · M&A & special situations analysed · FBRX Forte Biosciences, Inc. fresh SUPREME Forte Biosciences’ $77-per-share cash-acquisition thesis was resolved by the 2026-08-27 merger completion. Official restoration of the former common equity would reopen the case; Nasdaq records 2026-08-26 as its last trading date. Earnings inflection · Precision biotech & therapeutics · M&A & special situations analysed · KALV KalVista Pharmaceuticals, Inc. fresh SUPREME KalVista Pharmaceuticals’ $27.00 cash-acquisition thesis was settled by Chiesi’s 2026-06-11 completion announcement. A renewed equity thesis would require documented restoration of the original common stock; the provisional September… Earnings inflection · M&A & special situations catalyst · LPRO Open Lending Corporation fresh SUPREME Open Lending Corporation’s $3.15 cash-acquisition story concluded with ANV’s confirmed completion on 2026-07-30. The public-equity narrative remains closed unless an official reversal or documented restoration of trading reopens it. Earnings inflection · Fintech & consumer credit · M&A & special situations analysed · OLPX Olaplex Holdings, Inc. fresh SUPREME Olaplex Holdings’ cash-acquisition thesis was resolved by Henkel’s 2026-07-07 completion and the end of Nasdaq trading. A newly listed standalone security would reopen equity analysis; Henkel’s 2026-11-10 release addresses only the… Earnings inflection · M&A & special situations catalyst · TBRG TruBridge, Inc. fresh SUPREME TruBridge’s $26.25-per-share cash acquisition completed on 2026-07-09, ending its standalone equity catalyst. September leadership integration concerns the acquirer; only an official restoration of the original listed equity would reopen… Earnings inflection · M&A & special situations · Managed care & health services analysed · ARX Accelerant Holdings HIGH Accelerant Holdings’ $20.25 cash acquisition by Thoma Bravo remains a completion thesis, with closing guided to the first half of 2027. Completion settles the case; a daily close below $18.25 or deal termination invalidates it. Earnings inflection · M&A & special situations catalyst · ESPR Esperion Therapeutics, Inc. HIGH Esperion Therapeutics’ cash-merger thesis was settled by the 2026-07-13 acquisition; only conditional commercial milestones remain. The common stock ceased trading, so the historical price invalidation no longer provides a prospective test. Earnings inflection · M&A & special situations analysed · GBTG Global Business Travel Group, Inc. fresh HIGH Global Business Travel Group’s $9.50-per-share Long Lake cash acquisition remains the thesis: completion settles the case, while a daily close below $9.00 invalidates it. Shareholders approved the merger on 2026-08-03, but the verified… Earnings inflection · M&A & special situations analysed · MKTX MarketAxess Holdings, Inc. HIGH MarketAxess’s $167-per-share cash acquisition by Intercontinental Exchange remains a completion story. Completion before a daily close below $155 would validate the case; the September 25, 2026 antitrust milestone is the next dated test. Earnings inflection · M&A & special situations catalyst · MRX Marex Group plc fresh HIGH Roll-up compounder in clean momentum continuation: the sell-side is now chasing price, with KBW $80, Barclays $76 and Piper $75 targets (Jul 9-15) leapfrogging the old $60 consensus, while the Bright Point clearing bolt-on (2026-07-09)… Cyclical recovery · M&A & special situations · AI datacenter infrastructure analysed · OGN Organon & Co. fresh HIGH Organon & Co.’s $14.00-per-share cash acquisition by Sun Pharma remains a completion thesis. Payment of the agreed consideration before a daily close below $13.00 would settle the case; the 2026-07-23 shareholder approval leaves regulatory… Earnings inflection · M&A & special situations analysed · PAYO Payoneer Global Inc. fresh HIGH Payoneer Global's $7.40-per-share cash acquisition now hinges on regulatory clearance and completion after September 14 shareholder approval. Payment before a daily close below $6.75 would resolve the thesis favorably; the vote alone does… Earnings inflection · M&A & special situations analysed · RAMP LiveRamp Holdings, Inc. fresh HIGH LiveRamp’s $38.50-per-share cash acquisition by Publicis remains a regulatory-completion thesis. Publicis reaffirmed year-end completion on 2026-09-16; closing by 2026-12-31 confirms the case, while a daily close below $35, termination or… Earnings inflection · M&A & special situations analysed · SAFT Safety Insurance Group, Inc. fresh HIGH Safety Insurance Group’s $105.00 cash-merger completion case now has HSR clearance and a 2026-11-03 shareholder vote. Completion requires the remaining approvals, while a daily close below $99 invalidates the price-convergence thesis. Earnings inflection · M&A & special situations analysed · SMTI Sanara MedTech Inc. HIGH Sanara MedTech's cash-and-stock acquisition by MIMEDX now has a 2026-09-30 shareholder vote; completion by year-end would settle the merger thesis. A daily close below $32.50 or failure to complete by 2026-12-31 invalidates that case. Earnings inflection · Medtech & diagnostics · M&A & special situations catalyst · TECH Bio-Techne Corp fresh HIGH Bio-Techne’s $73.00 cash acquisition by Merck KGaA remains a completion thesis, with the shareholder vote scheduled for 2026-09-23. The case resolves through payment after required approvals and is invalidated by a daily close below $70;… Earnings inflection · M&A & special situations catalyst · UTZ Utz Brands, Inc. HIGH Utz Brands’ $14.25 cash-acquisition story turns on completion in the company-guided fourth quarter of 2026. Closing fulfills the case; a daily close below $13.50 or failure to complete by 2026-12-31 invalidates it, while the September 11… Earnings inflection · M&A & special situations analysed · ACIW ACI Worldwide, Inc. MEDIUM Special-situation breakup narrative accelerating: Reuters (2026-07-17) reports ACI exploring a ~$1.5B sale of its Biller unit, which would surface sum-of-the-parts value and re-rate the faster-growing Payments Software segment. Q1 beat +… Special situation · M&A & special situations · Fintech & consumer credit catalyst · BOLD Boundless Bio, Inc. fresh MEDIUM Boundless Bio’s merger thesis pairs a planned $44–48 million cash distribution with a minority Serapha interest. Completion by 2026-12-31 with that distribution intact would confirm the case; a weekly close below $2.40 would invalidate its… Earnings inflection · M&A & special situations · Rare disease & gene therapy catalyst · CCC CCC Intelligent Solutions Holdings Inc. MEDIUM Cheap, high-margin insurtech SaaS put in play: a Morgan Stanley-run sale process plus a fresh Elliott activist stake. Shares popped ~13% to ~$6 on the 2026-07-09 Reuters report yet still sit below a plausible PE take-out. The trade is… Earnings inflection · M&A & special situations analysed · CMCO Columbus McKinnon Corporation MEDIUM First full combined quarter post-Kito Crosby beat hard (adj EPS $0.61 vs $0.27 est) and drove a guidance raise on all three lines on 2026-07-30; the leg being bought is deleveraging from 4.9x toward sub-4x by FY28 on $70M of synergies. No… Special situation · Cyclical industrials · M&A & special situations catalyst · CXT Crane NXT, Co. fresh MEDIUM The post-print give-back stopped rather than reversed: $50.20 on 2026-08-21 and $50.06 on 2026-09-04, RSI back to 49.5, with the $47 washout shelf untested since the 2026-08-19 $48.06 open. The sell-side anchor reset lower in the same… Special situation · M&A & special situations · Cyclical industrials analysed · IRWD Ironwood Pharmaceuticals, Inc. fresh MEDIUM Ironwood Pharmaceuticals’ LINZESS cash generation supports a recovery toward the market’s $5.39 high, tested by annual guidance and year-end debt reduction. A weekly close above $5.39 completes the price case; a weekly close below $3.80… Earnings inflection · Precision biotech & therapeutics · M&A & special situations analysed · LILA Liberty Latin America Ltd. fresh MEDIUM Liberty Latin America's break-up story needs an announced Puerto Rico and US Virgin Islands separation form and completion window by the next quarterly report. That milestone confirms the case unless a weekly close below $7.30 invalidates… Defensive · M&A & special situations · Emerging markets analysed · LNC Lincoln National Corp. MEDIUM Lincoln National Corporation’s legacy-risk transfer supports a re-rating case, with Talcott completion in Q4 2026 and a weekly close above $47 confirming it. A weekly close below $42 or failure to close the deal by 2026-12-31 invalidates… Special situation · Medtech & diagnostics · M&A & special situations analysed · NEOG Neogen Corporation MEDIUM Neogen’s turnaround rests on Food Safety growth and Genomics-funded debt reduction. The confirmed 2026-10-07 investor day precedes the estimated October results test; a revenue miss, lost sale funding or a weekly close below $11.00 would… Special situation · Medtech & diagnostics · M&A & special situations catalyst · PD PagerDuty, Inc. fresh MEDIUM The read has flipped from value trap to ownership story. Price reclaimed the 200-DMA (~$10.30 on 2026-07-17, +13% in three weeks), Truist lifted its PT to $11 on 2026-07-09, and the 2026-07-14 addition of Alex Shootman — who sold Workfront… Special situation · AI enterprise software · M&A & special situations analysed · PRGS Progress Software Corporation fresh MEDIUM Disciplined software roll-up ("Total Growth Strategy") re-rated by a fresh catalyst cluster: Q2 beat + FY guide raise (2026-06-30) and the $400M Domo buy (2026-07-22). Special-situations theme active, but a maturing low-beta compounder —… Special situation · AI enterprise software · M&A & special situations catalyst · RLYB Rallybio Corporation fresh MEDIUM Rallybio’s Avenzo merger thesis combines a cash distribution with residual oncology exposure; completion and a declared distribution would establish the outcome. A weekly close below $14 invalidates the price case, while failure to close… Earnings inflection · M&A & special situations · Oncology & immunology analysed · RMAX Re/Max Holdings, Inc. fresh MEDIUM Merger arb that finally got a date. DOJ granted HSR early termination 2026-07-13 and both special meetings are set for 2026-08-14, removing the regulatory leg. RMAX $11.10 vs ~$11.86 blended (5.150 REAX at $2.21 plus the prorated $13.80… Earnings inflection · M&A & special situations · Housing, homebuilders & proptech analysed · ACB Aurora Cannabis Inc. fresh LOW Aurora Cannabis's takeover thesis requires improved Curaleaf terms or a competing definitive offer before a weekly close below $3.40. Curaleaf's 2026-09-14 regulatory application advances the dispute, but its 2026-09-15 letter retained… Earnings inflection · M&A & special situations analysed · ACHR Archer Aviation Inc. LOW Archer Aviation’s acquisition-led recovery thesis failed when the 2026-09-11 weekly close of $5.58 breached its published $5.65 threshold. Completion of the Boeing transaction remains the business test, but cannot reverse that price… Compounder · Defense & aerospace · Physical AI & robotics analysed · ACLS Axcelis Technologies, Inc. fresh LOW Axcelis has stopped falling without being re-bid: $115.57 on 2026-08-28 to $115.08 on 2026-09-04, RSI(14) down to 22.0, 39.9% under the $191.6 high. What is left is a de-rated implant franchise plus an undated China SAMR ruling into the… Earnings inflection · Semi foundry & equipment · M&A & special situations catalyst · ANAB AnaptysBio, Inc. fresh LOW AnaptysBio’s Jemperli rights-reversion thesis turns on a written Chancery judgment; the September 25 brief advances the case without settling it. A judgment granting reversion before a weekly close below $52 would establish the thesis… Earnings inflection · M&A & special situations · Oncology & immunology catalyst · AZTA Azenta, Inc. LOW Azenta's cash-backed operating recovery needs positive organic growth at the next results and a weekly close above the August shelf at $32.04. The September 11 close of $30.85 leaves confirmation outstanding; a weekly close below $28… Special situation · Medtech & diagnostics · M&A & special situations catalyst · BAK Braskem S.A. fresh LOW Braskem's restructuring recovery depends on a binding parent plan that preserves listed equity without creditor-driven dilution. The 2026-09-24 subsidiary hearing tests the first agreement; the estimated 2026-11-22 parent creditor-support… Earnings inflection · Emerging markets · M&A & special situations catalyst · CCXI Churchill Capital Corp XI fresh LOW De-SPAC humanoid pure-play still bleeding premium: $17.07 (2026-08-14) → $14.57 (2026-08-21) → $13.40 (2026-09-04), RSI(14) down to 25.9. The only company-dated item since the 2026-07-14 confidential S-4 is an 2026-08-27… Earnings inflection · M&A & special situations · Physical AI & robotics catalyst · CNMD CONMED Corporation fresh LOW CONMED Corporation's sale-premium thesis failed its published $46 weekly-close test on 2026-09-18. A disclosed transaction would establish a new deal case; September operating commentary has not resolved the July sale report. Earnings inflection · Medtech & diagnostics · M&A & special situations analysed · CODI Compass Diversified LOW Compass Diversified’s asset-sale and debt-reduction story needs operating confirmation and recovery toward B. Riley’s $15 target before a weekly close below $11 breaks the thesis. The 2026-09-11 adjusted close of $11.01 leaves the existing… Special situation · M&A & special situations catalyst · CPIX Cumberland Pharmaceuticals Inc. LOW Cumberland Pharmaceuticals’ post-Apotex recovery depends on ifetroban results restoring clinical credibility. The case requires disclosed endpoint results followed by a weekly close above the September 11 high of $8.97 before a weekly… Special situation · M&A & special situations · Precision biotech & therapeutics analysed · CRTO Criteo S.A. LOW Criteo's recovery case rests on ChatGPT advertising translating into financial stabilization. Q3 contribution excluding traffic acquisition costs reaching $241 million without another annual outlook cut would validate it; a daily close… Earnings inflection · M&A & special situations · AI datacenter infrastructure catalyst · EPC Edgewell Personal Care Company fresh LOW Edgewell Personal Care's takeover-and-recovery thesis needs renewed deal evidence or confirmed growth to restore the market's $29.50 high. A weekly close above $29.50 would complete the price case; a weekly close below $25 would invalidate… Earnings inflection · M&A & special situations analysed · FWRD Forward Air Corporation LOW Busted-merger workout losing its bid: the +48% June bounce to $14.87 (on a speculative Amazon-bolt-on thesis) has faded ~13% to ~$13, whole-company sale is now reported "unlikely," and the 2026-07-10 chairman exit forfeited… Earnings inflection · Cyclical industrials · Freight & logistics analysed · IHRT iHeartMedia, Inc. LOW M&A leg is dead — no SiriusXM headline since the 2026-05-29 NYT "stalled" report and the April spike fully round-tripped ($6.33 high → $3.86 on 2026-08-07, -39%). What is left is a binary: Q2 print 2026-08-10 after the close is the first… Earnings inflection · M&A & special situations · Cyclical industrials catalyst · LILAK Liberty Latin America Ltd. fresh LOW Post-catalyst drift: the $500M preferred special dividend and the June Malone/Nair insider cluster already drove a ~70% run off $4.76 to ~$8.30, and the tape has stalled at $7.33. Citi cut to Neutral 2026-07-10 with a $8 target already… Defensive · M&A & special situations · Emerging markets analysed · MGM MGM RESORTS INTERNATIONAL fresh LOW Take-private process went live: WSJ reported substantive Diller talks 2026-07-10, MGM seated a special committee mid-July, and the board reportedly views $48.30 as too low — so the trade is now a bump handicap, not a growth story. At… Earnings inflection · M&A & special situations catalyst · NEXA Nexa Resources S.A. fresh LOW Cyclical zinc-recovery confirmed and fully priced: Q1 EBITDA +126% YoY and Aripuanã's record 13kt ramp drove a run to the $16.89 high, but the equity now chops $12–13 while LME zinc printed a fresh 2026 high near US$3,622 — a bearish… Special situation · M&A & special situations analysed · OPI Office Properties Income Trust Common shares of beneficial interest fresh LOW Office Properties Income Trust's recovery depends on refinancing completion and property sales validating post-reorganization equity. Expected financing settlement on 2026-09-24 supplies a dated test; the price case requires a weekly close… Defensive · M&A & special situations catalyst · PBI Pitney Bowes Inc. fresh LOW PBI broke the $17.62 shelf to a fresh 52-week high $18.62 (Jul 16) — the buyback/cost-cut re-rate is now extending, not consolidating. But revenue still shrinks ~3% YoY, consensus PT $16.43 sits below spot, and Q2 prints after close Jul… Special situation · M&A & special situations · Cyclical industrials catalyst · PLTK Playtika Holding Corp. fresh LOW Playtika Holding Corp.'s remaining recovery case depends on completed refinancing and preserved revenue guidance. Confirmation requires execution of the authorized bond financing and retention of the $2.75 billion full-year revenue floor… Earnings inflection · M&A & special situations analysed · RPAY Repay Holdings Corporation fresh LOW The Visa-headline pop has round-tripped — $4.01 on 2026-08-21 back to $3.88 on 2026-09-04 — while the deal file stayed silent: the only company items since are an 2026-08-26 NxtEdge AP partnership and a 2026-09-03 IR hire, leaving… Earnings inflection · M&A & special situations · Fintech & consumer credit analysed · SEER Seer, Inc. fresh LOW The take-private ladder has stalled into a stand-off: the $2.55 Radoff-JEC bid lapsed unanswered on 2026-08-10, and the group's 2026-08-13 release demanding the board disclose an evaluation timeline has drawn no company reply through the… Earnings inflection · M&A & special situations · Medtech & diagnostics catalyst · SITM SiTime Corporation fresh LOW MEMS-timing picks-and-shovels story is fundamentally intact — Q1 datacenter revenue +158% YoY to 67% of sales, Renesas timing deal closed July 1 — but the momentum leg has broken: ~$550 on July 18 is ~39% off the May 11 all-time-high close… Cyclical recovery · AI datacenter infrastructure · M&A & special situations analysed · SYNA Synaptics Incorporated fresh LOW Synaptics' fixed-ratio onsemi merger remains the central thesis; completion on announced terms before a weekly close below $90 would validate it. The September 15 annual proxy does not establish a merger-vote date. Earnings inflection · M&A & special situations · Analog semiconductors catalyst · TIC TIC Solutions, Inc fresh LOW Post-merger re-rate: engineering/geospatial backlog hit a record $1.18B (+20% YoY) on 2026-08-06 while legacy inspection fell ~5.5% combined, and UBS's 2026-08-11 upgrade (Buy, PT $12.50 from $11.00) prices an inflection that Q2's +2.5%… Special situation · M&A & special situations analysed · TORO Toro Corp. fresh LOW Panagiotidis shipping shell (NOT lawnmower TTC) ran 1.93→8.50 on a sub-NAV/special-dividend story that is now fully paid out and closed. Six weeks of dead tape since the 2026-06-05 payout ($3.8M cash + 5,707,246 NEW shares); on a true… Retail squeeze · Freight & logistics · M&A & special situations analysed · TRIP TripAdvisor, Inc. LOW Tripadvisor's residual-value case rests on TheFork proceeds and Experiences growth supporting a weekly recovery above $10. A weekly close below $9 invalidates the price case; failure to close TheFork by December 31, 2026 defeats the… Special situation · Travel & leisure · M&A & special situations analysed · UNIT Uniti Group Inc. fresh LOW Hyperscaler dark-fiber demand turned the post-Windstream deleveraging grind into a growth story (~$1.5B disclosed funnel, $68.7M of Q1 IRU revenue from one hyperscaler), but the June re-rate to ~$11 has stalled in a three-week range above… Special situation · AI datacenter infrastructure · M&A & special situations catalyst · VECO Veeco Instruments Inc. LOW Merger-arb tracking stock for Axcelis: fixed 0.3575 ACLS/VECO, both votes cleared 2026-02-06, only China SAMR remains before the 2026-09-30 outside date. ACLS's slide to ~$134 de-pegged VECO to a premium over the exchange ratio (~$48) —… Earnings inflection · M&A & special situations · Semi foundry & equipment catalyst · XHG XChange TEC.INC LOW XChange TEC's AI-insurance acquisition story needs a definitive First Cycle agreement and price recovery to validate it. The case requires a daily close above the $4.62 high reported as of 2026-09-11 before a daily close below that date's… Retail squeeze · M&A & special situations · AI datacenter infrastructure analysed · XRX Xerox Holdings Corporation LOW Distressed-deleveraging special situation that round-tripped its June activist pop into a binary 2026-07-30 Q2 print. At ~$2.60 it sits below the $2.75 Hold consensus and inside the $2.25–$2.50 target band; anchor buyer STARTEEPO (8.8M sh,… Special situation · M&A & special situations · Cyclical industrials catalyst · XTLB XTL Biopharmaceuticals Ltd. LOW XTL Biopharmaceuticals' psychedelic recovery case requires a disclosed Psyga trial start or binding ibogaine partnership and a weekly close above the June 30, 2026 financing reference of $2.70. A weekly close below $2.20 invalidates it;… Special situation · Precision biotech & therapeutics · M&A & special situations analysed · ZENA ZenaTech, Inc. LOW ZenaTech's recovery case requires a priced commercial drone-service contract and a weekly close above the market's August 28 close of $1.71. A weekly close below $1.52 invalidates that case; September's development announcements have not… Defensive · Defense & aerospace · Cyclical industrials catalyst ·
Browse another filter